Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Chubb
Novartis
Harvard Business School
Queensland Health
Boehringer Ingelheim
Cipla
AstraZeneca
Colorcon
US Department of Justice

Generated: January 16, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,888,362

« Back to Dashboard

Which drugs does patent 7,888,362 protect, and when does it expire?

Patent 7,888,362 protects REXULTI and is included in one NDA.

This patent has twenty-six patent family members in twenty-five countries.
Summary for Patent: 7,888,362
Title:Piperazine-substituted benzothiophenes for treatment of mental disorders
Abstract: The present invention provides a heterocyclic compound represented by the general formula (1): The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety. ##STR00001##
Inventor(s): Yamashita; Hiroshi (Tokushima, JP), Ito; Nobuaki (Tokushima, JP), Miyamura; Shin (Tokushima, JP), Oshima; Kunio (Tokushima, JP), Matsubara; Jun (Tokushima, JP), Kuroda; Hideaki (Tokushima, JP), Takahashi; Haruka (Tokushima, JP), Shimizu; Satoshi (Tokushima, JP), Tanaka; Tatsuyoshi (Tokushima, JP)
Assignee: Otsuka Pharmaceutical Co., Ltd. (Tokyo, JP)
Application Number:11/659,005
Patent Claim Types:
see list of patent claims
Compound; Process;

Drugs Protected by US Patent 7,888,362

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Otsuka Pharm Co Ltd REXULTI brexpiprazole TABLET;ORAL 205422-001 Jul 10, 2015 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Otsuka Pharm Co Ltd REXULTI brexpiprazole TABLET;ORAL 205422-002 Jul 10, 2015 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Otsuka Pharm Co Ltd REXULTI brexpiprazole TABLET;ORAL 205422-003 Jul 10, 2015 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Otsuka Pharm Co Ltd REXULTI brexpiprazole TABLET;ORAL 205422-004 Jul 10, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Otsuka Pharm Co Ltd REXULTI brexpiprazole TABLET;ORAL 205422-005 Jul 10, 2015 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Otsuka Pharm Co Ltd REXULTI brexpiprazole TABLET;ORAL 205422-006 Jul 10, 2015 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,888,362

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2005-116698Apr 14, 2005
PCT Information
PCT FiledApril 12, 2006PCT Application Number:PCT/JP2006/308162
PCT Publication Date:October 26, 2006PCT Publication Number: WO2006/112464

Non-Orange Book US Patents Family Members for Patent 7,888,362

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,839,637 Piperazine-substituted benzothiophenes for treatment of mental disorders ➤ Subscribe
8,349,840 Piperazine-substituted benzothiophenes for treatment of mental disorders ➤ Subscribe
8,618,109 Piperazine-substituted benzothiophenes for treatment of mental disorders ➤ Subscribe
9,480,686 Piperazine-substituted benzothiophenes for treatment of mental disorders ➤ Subscribe
9,206,167 Piperazine-substituted benzothiophenes for treatment of mental disorders ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,888,362

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 053577 ➤ Subscribe
Austria 496911 ➤ Subscribe
Australia 2006237905 ➤ Subscribe
Brazil PI0609785 ➤ Subscribe
Canada 2602247 ➤ Subscribe
China 101155804 ➤ Subscribe
Cyprus 1111206 ➤ Subscribe
Germany 602006019838 ➤ Subscribe
Denmark 1869025 ➤ Subscribe
European Patent Office 1869025 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Dow
Novartis
Harvard Business School
UBS
Johnson and Johnson
Teva
Accenture
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot